Company Overview and News

13
Trade of the Day: Applied Optoelectronics, Inc. (AAOI)

2018-10-15 investorplace - 1
To receive further updates on this Applied Optoelectronics, Inc. (NYSE:AAOI) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
AAOI

33
AAOI / Applied Optoelectronics, Inc. FORM 8-K (Current Report)

2018-10-12 sec.gov - 21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AAOI

34
AAOI / Applied Optoelectronics, Inc. FORM 8-K (Current Report)

2018-10-10 sec.gov - 22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AAOI

51
Most Heavily Shorted Stocks Tank In September

2018-09-28 seekingalpha - 12
We published our regularly updated Short Interest Report earlier today in order to show clients which areas of the market are seeing the biggest increases and decreases in short interest levels. A supplement to the report is the table below highlighting the most heavily shorted stocks in the S&P 1500.
DDS MDXG MDCO AAOI ICHR

12
Market Snapshot: S&P 500 poised for best quarter since 2013

2018-09-28 marketwatch
U.S. stocks edged upward on Friday, the last trading day of September, as investors sorted through a batch of economic data that painted a mixed picture of the economy. Major indexes were mostly set for a week of solid losses though they have performed well over for the month and the quarter.
NDAQ AAOI

26
A Downgrade Wounded AAOI Stock, but Trump Could Kill It

2018-09-28 investorplace - 7
Optical device and component manufacturer Applied Optoelectronics (NASDAQ:AAOI) has suffered tremendous choppiness over the past two years. Unfortunately, things got even more wild in the past 24 hours, with AAOI stock losing 9.5% in the markets.
TWTR AAOI

13
Applied Optoelectronics' stock plummets after revenue guidance cut

2018-09-28 marketwatch - 1
Shares of Applied Optoelectronics Inc. AAOI, -14.28% plummeted 22% in premarket trade Friday, after the optical components maker slashed its third-quarter revenue outlook, citing an "issue" identified with a percentage of lasers within a specific customer environment. The company now expects third-quarter revenue of $55 million to $58 million compared with previous guidance of $82 million to $92 million, and the FactSet consensus of $88.
AAOI

14
Finisar may have benefited from Applied Opto's stumbles, says Piper Jaffray

2018-09-28 marketwatch - 1
Shares of Applied Optoelectronics Inc. AAOI, -14.03% are down 12.7% in Friday morning trading after the company cut its revenue forecast owing to a problem with a small portion of 25G lasers related to a specific customer. Piper Jaffray analyst Troy Jensen thinks the rest of the industry looks fine and argued that Finisar Corp. FNSR, +0.34% might have benefited by the quality issues at Applied Opto.
FNSR AAOI

12
Story Stocks: Applied Optoelectronics down sharply on lowered Q3 revenue guidance (AAOI)

2018-09-28 briefing
The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.
AAOI

15
AAOI / Applied Optoelectronics, Inc. FORM 8-K (Current Report)

2018-09-28 sec.gov - 3
UNITED STATES SECURITIES AND
AAOI

17
Applied Optoelectronics Stock Is a Falling Machete That’s Worth Catching

2018-09-27 investorplace - 5
Yesterday, the stock market moved on headlines from the U.S. Federal Reserve decision to raise rates. This morning, Applied Optoelectronics (NASDAQ:AAOI) is moving on its own set of headlines and it’s not looking good for AAOI stock.
83GK 84GK AAOI

89
Top Analyst Upgrades and Downgrades: AMD, Amazon, Apple, Bed Bath & Beyond, Citigroup, Mastercard, Paypal, Square, Visa and More

2018-09-27 247wallst - 4
Stocks were marginally higher on Thursday after Wednesday’s rate hike by the Federal Reserve. The odds are still very high for another interest rate hike as soon at the December FOMC meeting. Many investors have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
V C AMZN ALDX AAPL MA TRI AMD AAOI BBBY

52
Applied Optoelectronics: Lost Facebook Revenue To Deliver The Next Major Blow

2018-09-27 seekingalpha - 1
Applied Optoelectronics ("AAOI") has rallied ~50% from its April lows in response to management optimism that revenue will inflect positively in 2H18.
FB AMZN AAOI INTC

12
Applied Optoelectronics: Buy On Concerns, Sell On Euphoria

2018-09-25 seekingalpha
As AAOI is a healthy business with strong fundamentals and positive long-term business momentum, I believe the situation presents an unparalleled opportunity to load up on the company's shares.
PS AAOI

AAOI : Applied Optoelectronics Stock Analysis and Research Report

2017-10-02 - Asif

Applied Optoelectronics is a leading, vertically integrated provider of fiber-optic networking products, primarily for four networking end-markets: internet data center, cable television, or CATV, fiber-to-the-home, or FTTH, and telecommunication, or telecom. The company design and manufacture a range of optical communications products at varying levels of integration, from components, subassemblies and modules to complete turn-key equipment. In designing products for its customers, Applied Optoelectronics begins with the fundamental building blocks of lasers and laser components. From these foundational products, the company design and manufacture a wide range of products to meet its customers’ needs and specifications, and such products differ from each other by their end market, intended use and level of integration. The company primarily focused on the higher-performance segments within all four of its target markets, which increasingly demand faster connectivity and innovat...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 03823U102